Drug Profile

IBRX 042

Alternative Names: hAd5-HPV E6.ETSD-IRES-E7.ETSD vaccine; IBRX-042

Latest Information Update: 19 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ImmunityBio
Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

14 Jun 2024 Phase-I clinical trials in Cancer (Second-line therapy or greater) in USA (Injection) (NCT05976828)
09 Aug 2023 ImmunityBio plans a phase I trial in Cancer (In adults, In the elderly, Second line therapy or greater) in August 2023 (NCT05976828)
25 Apr 2022 ImmunityBio plans the phase I/II QUILT 3.100 trial for HPV-associated Head and neck cancer, lower genitourinary and Cervical cancer (Combination therapy) (SC) in 2022

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com